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Abstract 
 
Background 
In hypertensive patients, the long-term cardiovascular (CV) and all-cause mortality effects of alternative blood 
pressure (BP)- lowering regimens and of lipid- lowering treatment are not well documented, particularly in a 
clinical trial setting. The ASCOT Legacy Study reports mortality outcomes after 16 years follow-up of UK 
participants in the original trial.  
 
Methods 
8580 UK-based hypertensive ASCOT patients (mean age, 64.1 years) were followed post- trial for all-cause and 
CV mortality (median follow-up, 15·7 years). At baseline, all patients were randomized, using a 2x2 factorial 
design, to the BP-lowering arm (BPLA): either amlodipine- (4305) or atenolol- (4275)-based treatment. Of 
these, 4605 (54%) patients with total cholesterol ≤ 6·5 mmol/L and with no previous lipid-lowering treatment, 
were further randomised to either atorvastatin (2317) or placebo (2288)- into the lipid-lowering arm (LLA). The 
remaining 3875 patients formed the non-LLA group. A team of two physicians independently adjudicated all 
causes of death. 
 
Results 
3282 (38·3%) patients died; 1640 (38·4 %) and 1642 (38·1 %) of those allocated to atenolol- and amlodipine-
based treatment respectively. 1768 deaths occurred in those assigned to LLA; 903 (39·5%) and 865 (37·3%) in 
those allocated to placebo and atorvastatin respectively. Of all deaths, a third (1210) were from CV-related 
causes. Amongst those in BPLA, there was no overall difference in all-cause mortality, but there were 
numerically fewer CV deaths (adjusted hazard ratio [HR] 0·90 [95% confidence interval, 0·81 to 1·01, p= 
0·0776]) and significantly fewer stroke deaths (adjusted HR 0·71 [0·53 to 0·97], p=0·0305) in the amlodipine-
based compared with the atenolol- based treatment groups. There was no interaction between treatment 
allocation in the BPLA and the LLA. However, in the non-LLA group, there were fewer CV deaths (adjusted 
HR 0·79 [0·67 to 0·93], p = 0·0046) amongst those assigned to amlodipine-based compared with atenolol-based 
treatment (test for interaction test between the two BP treatments and allocation to LLA or not, p=0·0220).  
Amongst those in LLA, there were significantly fewer CV deaths (HR 0·85 [0·72 to 0·99], p=0·0395] in those 
assigned to statin vs. placebo, and numerically fewer all-cause and coronary heart disease deaths (HR 0·92 [0·84 
to 1·01], p=0·0913 and HR 0·78 [0·58 to 1·04], p=0·0884, respectively). 
 
Interpretation 
These findings demonstrate the long term beneficial effects on mortality from antihypertensive treatment with a 
calcium channel blocker-based treatment regimen and lipid-lowering with a statin: patients on amlodipine-based 
treatment had a fewer stroke deaths, and patients on atorvastatin had fewer CV deaths more than ten years after 
trial closure. Overall, the ASCOT Legacy study supports the view that interventions on blood pressure and 
cholesterol are associated with long term benefits on cardiovascular outcomes. 
 
Funding 
The ASCOT Legacy study was investigator initiated and in part funded by Pfizer, New York.  
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Introduction 
 
Guidelines for the management of patients with hypertension highlight the importance of blood pressure control, 
although the target blood pressures, particularly systolic pressure, remain controversial. Some guidelines 
advocate preferred drug treatment regimens1,2 based on the results of cardiovascular (CV) disease outcome trials 
such as the Anglo-Scandinavian Cardiovascular Outcomes Trial (ASCOT)3 and Avoiding Cardiovascular 
Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trials,4,5 
whereas others simply focus on blood pressure control irrespective of particular drug classes.6-10 The trials on 
which the guidelines are based typically involved a duration of follow up around 5 years.  
 
Previously, hypertension trials of active drug treatment compared with placebo, with substantial post 
randomization (in-trial) blood pressure differences between the two arms, have been linked to longer-term 
legacy benefits in favour of the active treatment arm.11 In comparison, long-term post-trial follow-up data from 
trials comparing two active treatments is sparse.12 It is uncertain, therefore, if more recent trials which compared 
active treatment regimens and demonstrated the benefits of a regimen based on a calcium channel blocker 
(CCB) and an angiotensin-converting enzyme (ACE) inhibitor, 3,4 would have a long-lasting beneficial effect. 
Several long-term post-trial follow-up of placebo-controlled trials of statins have been reported,13,14,15 which 
have demonstrated persistent legacy benefits in those previously assigned statin, but none involving 
hypertensive patients who were also assigned an intervention with different antihypertensive strategies. 
 
ASCOT was designed to compare two antihypertensive treatment strategies and, in a factorial design, to 
compare atorvastatin with placebo.16 
 
In the present report we have evaluated the mortality data from the cohort of patients originally recruited into 
ASCOT from the UK (the ASCOT Legacy study), approximately16 years after entry into the trial and ten years 
after trial closure to establish whether assignment to either of the original blood pressure- lowering regimens, or 
to atorvastatin compared with placebo, conferred long-term legacy benefits on both all-cause and cause-specific 
mortality outcomes.  
 
 
Methods 
The detailed ASCOT protocol, including study design, conduct, and baseline characteristics has been 
published16 and further detailed information is available on the ASCOT website (www.ascotstudy.org).  
 
ASCOT Trial and patient profile 
Briefly, ASCOT was designed to compare two antihypertensive treatment strategies, amlodipine to which 
perindopril was added as necessary (amlodipine-based) and atenolol, to which bendroflumethiazide was added 
as necessary (atenolol-based) (the blood pressure-lowering arm [BPLA]) and, in a 2x2 factorial design, for those 
with total cholesterol of < 6·5 mmol/L, and not currently taking a statin or a fibrate, to compare atorvastatin and 
placebo (the lipid-lowering arm [LLA]).  
 
This population consisted of hypertensive men and women, aged 40 to 79 years at randomisation, with at least 
three additional risk factors for CV disease, but with no history of prior coronary heart disease (CHD) events, 
currently treated angina, or a recent cerebrovascular event within three months from randomization. The 
primary outcome was non-fatal myocardial infarction and fatal CHD. Patients were originally recruited between 
February 1998 and May 2000, mostly from family practices. In the Nordic countries, individual patients from 
686 family practices were randomized, and in the United Kingdom (UK) and Ireland, most randomized patients 
were referred from family practices to regional study centres.  
 
In all, 19257 patients were randomized to the BPLA, and of these, 10240 were randomized to the LLA. 9017 
were in the non-LLA group, of whom, about a third were on previous lipid-lowering or aspirin therapy. 
 
In late 2002, at the recommendation of the Data Safety Monitoring Board, the LLA was stopped prematurely,17 
after a median follow-up of 3·3 years, on account of substantial benefits of atorvastatin on the primary endpoint. 
These patients continued to be followed up until the end of the BPLA. During that period, these LLA-patients 
were offered open-labelled statin, and approximately two thirds accepted, in addition to their assigned blood 
pressure--lowering treatment. 
 
The BPLA was also prematurely stopped (at the recommendation of the Data Safety  Monitoring Board), mainly 
on account of significantly higher mortality amongst those allocated to  atenolol-based treatment  compared with 
4 
 
those on  amlodipine-based treatment. Database lock was in June 2005, with the last follow-up of patients 
ranging from December 2004 to April, 2005.3 
 
The study conformed to Good Clinical Practice guidelines and the Declaration of Helsinki. The protocol and all 
subsequent amendments were reviewed and ratified by central and regional ethics review boards in the UK and 
by national ethics and statutory bodies in Ireland and the Nordic countries (Sweden, Denmark, Iceland, Norway, 
and Finland). 
 
 
ASCOT Legacy cohort 
All 8580 ASCOT trial patients from the UK, form the cohort of the ASCOT Legacy study. All these patients 
were followed until the end of the BPLA, during which period 717 died. Of the remainder, 7302 (from all but 
two trial sites in the UK, where consent from the patients for the follow-up was not obtained) were flagged for 
death with the Office for National Statistics and the General Register Office for Scotland for post trial follow-
up. In this report, we have used all reported deaths on or before 31st December, 2015.  However, there are no 
data on morbidity and treatment after the end of the BPLA.  
 
A team of two physicians independently adjudicated the cause of death, using pre-specified criteria consistent 
with the definitions used during the in-trial period. In these analyses, we report on all-cause mortality, and 
deaths from CV and non-CV causes. All CV deaths were further adjudicated to report on deaths due to CHD or 
stroke. Similarly, non-CV deaths were sub-categorized to report on cancer-related deaths.  
 
Statistical methods 
All analyses were performed using the intention-to-treat principle, and thus in-trial follow-up is included for 
those 561 patients (from two sites) who were not flagged after the closure of the BPLA, and those who dropped-
out of the BPLA early. For those still alive, censoring was defined as the end of follow-up (31st December 
2015) or the end of BPLA for those survivors who did not consent. The end of the LLA period was defined as 
1st October, 2002 and the end of the BPLA was the last follow-up before the database lock in June, 2005. 
 
For both BPLA and LLA, and for each death outcome, separate Cox Proportional Hazards models were 
developed to estimate hazard ratios and 95% confidence intervals (CIs) comparing treatment groups. Both 
unadjusted and adjusted analyses were conducted. For analysis of each cause-specific death, all deaths from 
other causes were handled as censorings. We adjusted for the following pre-specified covariates at baseline: age, 
sex, ethnicity, age at leaving full-time education (reflecting socio-economic status [SES]), body-mass index 
(BMI), systolic blood pressure, total cholesterol, the presence of diabetes, smoking history, and the other 
treatment comparison (for example, for the treatment group comparisons in the BPLA, we adjusted for the 
allocation to statin or a placebo, with a dummy variable for those in the non-LLA group). 
 
For each Cox model, the assumption of proportionality was tested using Schoenfield’s residuals,18 and we found 
no evidence of any deviation. We pre-specified tests for interaction between the two treatment comparisons: 
blood pressure lowering treatment regimens and allocation to statin or a placebo. Tests for interactions were also 
performed to determine whether the impact of the two blood pressure- lowering treatments differed between 
subgroups such as presence of diabetes, age, or allocation to the LLA or not. 
 
Statistical tests were two-sided and a P-value of <0·05 was considered statistically significant. All statistical 
analysis was performed using STATA 15 (STATA Corporation, College Station, TX, USA). 
 
Role of the funding source  
The original ASCOT-Trial was conceived, designed, and coordinated by an investigator-led independent 
Steering Committee with two non-voting members from the principal funding source (Pfizer). Data collection, 
analysis, and interpretation and preparation of all reports were done independently of the funding sources. 
The ASCOT-legacy cohort was investigator initiated and led.  Data collection, analysis, and interpretation and 
preparation of all reports were done independently. There was no inputs, or any kind of involvement, from any 
of the funding body (Foundation for Circulatory Health, and Pfizer). All authors had full access to all the data in 
the study and had final responsibility for the decision to submit for publication. 
 
 
Results: 
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ASCOT Legacy cohort 
The ASCOT Legacy cohort consisted of 8580 hypertensive patients from the UK, with mean age at baseline 
64.1 years. Baseline characteristics of these patients were similar to those randomized from the Nordic 
countries, except that those in the UK ASCOT Legacy cohort were more ethnically diverse (10% vs 1%, non-
Caucasians), with more males ( 81·1% vs 72·9%) and fewer current smokers (23·8% vs 36·1%). 
 
Table 1 shows the baseline characteristics of those in the ASCOT Legacy cohort, randomized to the BPLA 
(either amlodipine- (4305) or atenolol- (4275)-based treatments), and 4605 re- randomized to either atorvastatin 
(2317) or placebo (2288) in the LLA. Supplementary table S1 describes the baseline characteristics of those in 
the ASCOT Legacy cohort, randomized to the LLA or not, 3975 of whom were in the non-LLA group. 
Compared with those allocated to the LLA, the non-LLA group had more women, more patients with > 4 CV 
risk factors at baseline, and higher mean baseline total-and LDL-cholesterol, more with a history of previous use 
of  lipid- lowering therapy or previous vascular disease. 
 
The trial profile in Figure 1 describes numbers of patients and deaths by randomized treatment allocations of 
the ASCOT Legacy cohort. During a median follow-up of 15·7 years (interquartile range [IQR] 9·7 to 16·4 
years), 3282 (38·3%) of all patients died: 1640 (38·4 %) and 1642 (38·1 %) in those allocated to atenolol- and 
amlodipine-based treatment respectively. 1768 (58%) of all deaths occurred in those assigned to LLA; 903 
(39·5%) and 865 (37·3%) in those allocated to placebo and atorvastatin respectively. Of all deaths, a third 
(1210) were from CV-related causes. 
  
ASCOT Legacy: the BPLA 
Table 2a describes the number of events and incidence rates (per 100 person years) for both total and cause 
specific mortality by the two BP-lowering treatment regimens for the in-trial period, post-trial period and 
throughout all follow-up. During the in-trial period (median 5·5 years follow-up), those on atenolol-based 
treatment had more deaths compared with those on amlodipine-based treatment both for all-causes and CV- 
mortality, and for the CHD- and stroke- mortality components of the CV mortality. However, during the post-
trial period (an extra 10·7 years of median follow-up) no additional treatment differences in mortality were 
noted, except for stroke mortality, where the differential in the event rates amongst those on 2 treatment 
regimens persisted.  
 
Table 3a demonstrates that overall (during a median follow-up of 15·7 years), amongst those in the BPLA, 
there was no statistically significant treatment difference in all-cause mortality, but there were numerically 
fewer CV deaths (adjusted hazard ratio [HR] 0·90 [95% confidence interval, 0·81 to 1·01, p= 0·0776]) and 
significantly fewer stroke deaths (adjusted HR 0·71 [ 0·53 to 0·97], p=0.0305) in the amlodipine-based, 
compared with the atenolol- based, treatment groups (see figures 2a to 2d [and supplementary figures S1 a and 
b], for Kaplan-Meier plots). Compared with the risks (HRs) during the in-trial period, the risk of CV death 
attenuated subsequently (HR from 0·74 [0·58 to 0·95] to 0·90 [0·81 to 1·01]). However, for stroke mortality, 
within the trial effect size (HR 0·69) was similar to that at the end of the follow-up (HR, 0.71), becoming 
statistically significant (p=0·0305) with the accrual of more events.  
 
There was no interaction between treatment allocation in the BPLA and the LLA (see supplementary table S2).  
Other subgroup analyses provided no evidence for treatment interactions with either age or diabetes status at 
baseline. However, there were differences in the effect of the two BP treatment regimens, based on whether a 
subject was allocated to the LLA or not (test for interaction, p=0·0220). Supplementary table S3 shows the 
number of events, and incidence rates, for cause-specific deaths in the two treatment groups, stratified by 
allocation to LLA or not (the non-LLA group). In the non-LLA group, compared with those on atenolol-based 
treatment, those allocated to amlodipine-based treatment had significantly fewer CV deaths (adjusted HR 0·79 
[0·67 to 0·93], p = 0·0046) and CHD deaths (adjusted HR 0·76 [ 0·59 to 0·93], p=0·0439, and numerically 
fewer stroke deaths (adjusted HR 0·67 [0·43 to 1·04], p= 0·0751) (see supplementary figures S2 a-d, for 
corresponding KM plots in the LLA and non-LLA group).  
 
ASCOT Legacy: the LLA 
Table 2b describes the number of events and incidence rates for the cause specific mortality amongst those 
assigned to atorvastatin or a placebo in the LLA of the ASCOT Legacy cohort; during the in-trial period, post-
trial period and throughout all follow-up.  Compared with those assigned to  placebo, those assigned to 
atorvastatin had numerically fewer all-cause -, CV - and CHD-deaths during both in trial and post-trial period. 
However, there was no evidence of a treatment difference in stroke deaths (see figures 3 a-d, for corresponding 
KM plots, and supplementary figures S3 a and b).  
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Table 3b presents estimates for these mortality differences between atorvastatin and placebo in the LLA of the 
Legacy cohort, both for in-trial period and overall follow-up. There were significantly fewer CV deaths (HR 
0·85 [0·72 to 0·99], p=0·0395] in those assigned to atorvastatin vs. placebo, with non-significant differences in 
the same direction for all-cause and coronary heart disease mortality (0.92 [0.84 to 1.01], p=0.0913 and 0.78 
[0·58 to 1·04], p=0·0884, respectively). Sub-group analyses by age or presence of diabetes at baseline showed 
no effect modification.  
 
 
Discussion 
These findings on hypertensive patients with no previous coronary event, demonstrate the long-term benefits 
from antihypertensive treatment with a CCB- based treatment regimen and lipid- lowering with a statin, in 
particular, assignment to amlodipine-(adding perindopril as required)- based treatment was associated with 
fewer stroke deaths throughout 16-years of follow-up (supplementary figure S4). We also confirm the long-term 
benefits of statin therapy in reducing the risk of CV deaths.13,14,15,19,20 This study is the first to report that both 
blood pressure- and lipid-lowering treatments confer such long-term benefits. Furthermore, findings for the 
higher risk sub-group in the non-LLA group, confirm the long-term benefits of blood pressure lowering 
therapies in such patients. Also, there are differences in the benefits conferred with the use of different blood 
pressure lowering regimens, even if the in- trial blood pressure control gained is similar (see supplementary 
table S4 a and b)  
 
The only other large trial to have studied CV outcomes of both antihypertensive therapy and lipid- lowering 
with statins, the Antihypertensive and Lipid Lowering to prevent Heart Attacks Trial (ALLHAT),21,22 compared 
different monotherapies with similar add on antihypertensive treatments. Both ASCOT and ALLHAT trials 
evaluated the potential benefits of statins in hypertensive patients. In ASCOT, atorvastatin was compared with 
placebo, and in ALLHAT, pravastatin was compared with “usual care”. Unfortunately in ALLHAT, many 
patients in the “usual care“ arm received statins and only a small difference in cholesterol between the treatment 
groups was achieved, which resulted in the trial being underpowered to compare effects on major cardiovascular 
endpoints. 22, 23 The findings from the extended follow-up of those assigned to three limbs of the 
antihypertensive study: chlorthalidone, amlodipine and lisinopril were mixed.24,25 The in-trial benefits apparent 
with the use of chlorthalidone vs. amlodipine and lisinopril, respectively, were no longer evident in the long-
term follow-up.  
 
In long-term follow-up of trials in hypertensive patients,11 in which active treatment was compared with 
placebo, and where blood pressure differences in the trials were associated with substantial reductions in CV 
events, a legacy or carry over effect has been observed in the post-trial period, 26-29 with long-term reductions – 
on average 9%, in mortality in the group previously receiving active treatment11.  However, in ASCOT, which 
compared different active (alternative) treatment strategies,16 the long-term outcome benefits associated with the 
amlodipine-based regimen could not be attributed to earlier differences in blood pressures during the trial.30 
First, as previously reported with the main trial outcome3 and a post-hoc analysis30, there was only a small 
difference in blood pressure of 2·9/1·8 mmHg between the two treatment arms. Also, in the ASCOT UK Legacy 
population overall mean differences in blood pressure recorded during the trial were only around 1·2/1·6 mmHg 
(supplementary table S4a). This small magnitude of blood pressure difference cannot account for the sustained 
and significant differences in the stroke mortality apparent in this long-term follow-up.   
 
Initially, we attributed the benefits of the amlodipine-based treatment to differences the in metabolic profile, 
including adverse effects of glycaemia associated with the atenolol-based therapy, and other differences 
including small changes in lipids and electrolytes.30 However, these changes alone were insufficient to explain 
the observed in-trial effects on mortality and CV events.30 We have subsequently shown other important 
differences between the two treatment arms, with atenolol-based treatment lowering central aortic pressure 
substantially less than amlodipine-based treatment.31  Also blood pressure variability was a major determinant of 
CV outcome in ASCOT,32 and was reduced to a much greater extent with the amlodipine- based  compared with 
the atenolol-based regimen.33 
 
We believe these mechanisms, and potentially others as yet unknown, are likely explanations for findings in 
ASCOT-BPLA, and that they also contribute to the long term benefits we have observed in the ASCOT Legacy 
population. We are in the process of further investigating these, together with studies on potential genetic and 
other biomarker predictors of CV events, which may explain the differences we have observed during this 16 
year follow-up.  
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For the blood pressure trial, the most striking treatment difference was in stroke death which, from our earlier 
reports, was closely associated with blood pressure variability33. Our observations also show that, whilst during 
the trial there was a significant reduction in CV mortality, this effect was attenuated in subsequent follow-up , 
except for stroke mortality, where the beneficial effect remained essentially the same even ten years after trial 
closure. These dilutional effects may reflect that after the trial, similar overall treatment strategies would have 
been used by both groups of patients. Nevertheless, by way of contrast, the persistence of the effect size on 
stroke deaths may reflect the close relationships that this outcome has with blood pressure treatment,34  
We also observed a differential legacy between the two treatment groups, according to the baseline risk of the 
patients. Thus, when evaluating the event rates in the two blood pressure treatment arms, amongst those 
randomised in the LLA compared with the non-LLA (table 4), for those assigned amlodipine-based treatment, 
there was little difference in  event rates for the stroke and CV  mortality, and very small differences in the CHD 
mortality. This implies that this combination of medications confers a similar effect irrespective of baseline risk. 
However, for those assigned the atenolol-based treatment there was, compared with those in the LLA, an excess 
event rate amongst those not included in LLA.  
 
Following early stopping of the LLA, the beneficial mortality effects of atorvastatin tracked, with little dilution 
of effect over the long-term. In the ASCOT-LLA Legacy cohort, the effect sizes of CV and all-cause mortality 
at the end of trial, and also 13 years later remained similar but, with an increasing number of events, the 
mortality benefits became more significant for CV deaths, with a trend towards long-term benefit for all cause 
and CHD mortality. Similar findings, particularly the relationship between the use of a statin and reduction in 
the cardiovascular mortality in long-term follow-ups have been reported in other trials,13,14,1519,20 but the 
mechanism for these durable and legacy effects remains unclear.  
 
These analyses have several limitations. After the trial closure, we have no data on anti-hypertensive and lipid-
lowering medications, and indeed other treatments. Thus, we cannot reliably ascertain what differences, if any, 
in post-trial blood pressures and their treatment existed in the longer term. However, after the closure of the 
LLA, a similar number of patients assigned to atorvastatin or placebo received a statin during the 2·2 year 
extension during final years of the BPLA of the trial.35 Another limitation is that we have no morbidity data 
following trial closure. We agree that the availability of such data would provide for a more comprehensive 
evaluation, and we are in the process of developing appropriate linkages to acquire them. However, we believe 
that the mortality data are robust. Generalizability of this population can be questioned. The patients in this 
cohort were of median age 64 years, hypertensive and with some common risk factors, which would make them 
fairly representative of those of similar age in the community. Indeed, in previous unpublished work, we have 
compared our population with the hypertensive patients from the community reported in the Health Survey of 
England and found them fairly similar. Lastly, these findings need replication in other studies. The biggest 
strength of this study is that it is the first to report on a large hypertensive cohort involving both blood pressure 
and lipid-lowering treatments and their impact on long-term mortality, with substantial power to evaluate 
mortality differences between treatments.  
 
Conclusion 
These legacy outcomes from the ASCOT trial demonstrate long term benefits from antihypertensive treatment 
with a CCB- based treatment regimen and lipid- lowering with a statin, 16 years after entry into the trial, and 
more than ten years following its closure. It is reported for the first time that the legacy benefit from the 
amlodipine-based regimen in reducing risk of stroke mortality appears independent of achieved blood pressure 
levels, and several possible explanations have been provided. The long term benefits of statins on CV mortality 
reduction are confirmed. Overall, our findings support the belief that interventions on blood pressure and 
cholesterol are associated with long term benefits on CV outcomes. 
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Table 1: Baseline characteristics of those in the ASCOT-Legacy cohort, randomized by blood pressure lowering arms and also by randomized 
atorvastatin or placebo in the LLA group 
 
* 5 patient with missing SES status. ** including 37 who were with 2 risk factors only; BPLA: blood pressure lowering arm; LLA: lipid-lowering arm; HDL: 
high density lipoprotein; LDL: Low density lipoprotein; TIA: transient ischemic attack. 
 
    
Baseline characteristics ASCOT-legacy  BPLA (n, 8580)  LLA (n, 4605) 
  Amlodipine 
(n, 4305) 
Atenolol 
(n, 4275) 
Atorvastatin 
(n, 2317) 
Placebo 
(n, 2288) 
  n (%), mean (SD) or median (IQR) n (%), mean (SD) or median (IQR) 
Age (years)  64 (8) 64 (8) 64 (8) 64 (8) 
Male gender Male 3492 (81·1%) 3468 (81·1%) 2016 (87·0%) 2004 (87·6%) 
Ethnicity White/Europid 3861 (89·7%) 3840 (89·8%) 2045 (88·3%) 2019 (88·2%) 
 South Asian 130 (3·0%) 109 (2·5%) 72 (3·1%) 80 (3·5%) 
 Oriental 7 (0·2%) 3 (0·1%) 2 (0·1%) 2 (0·1%) 
 Mixed/other 85 (2·0%) 86 (2·0%) 36 (1·6%) 33 (1·4%) 
 African 222 (5·2%) 237 (5·5%) 162 (7·0%) 154 (6·7%) 
Socio-economic status (age at leaving full time education)* 12-14 1282 (30·0%) 1272 (29·6%) 682 (29·8%) 658 (28·4%) 
 15-16 2091 (48·9%) 2165 (50·3%) 1121 (49·0%) 1119 (48·3%) 
 17-18 484 (11·3%) 465 (10·8%) 245 (10·7%) 287 (12·4%) 
 18+ 416 (9·7%) 400 (9·3%) 239 (10·5%) 252 (10·9%) 
 Missing  2 3 1 1 
Body mass index (kg/m2)  28·9 (4·7) 28·9 (4·6) 28·8 (4·9) 28·8 (4·6) 
Smoking status Current smoker  1035 (24·0%) 1006 (23·5%) 547 (23·6%) 541 (23·6%) 
Alcohol status Non-drinker 1088 (25·3%) 1089 (25·5%) 574 (24·8%) 571 (25·0%) 
 1-13 units per week 1816 (42·2%) 1831 (42·8%) 1010 (43·6%) 983 (43·0%) 
 14+ units per week 1401 (32·5%) 1355 (31·7%) 733 (31·6%) 734 (32·1%) 
Systolic blood pressure (mmHg)  162 (18) 162 (17) 162 (17) 162 (18) 
Diastolic blood pressure (mmHg)  92 (10) 92 (10) 92 (10) 93 (10) 
Heart rate (bpm)  71 (13) 71 (12) 70 (12) 71 (13) 
Total cholesterol (mmol/L)  5·9 (1·1) 5·9 (1·1) 5·5 (0·8) 5·5 (0·8) 
HDL-cholesterol (mmol/L)  1·3 (0·4) 1·3 (0·4) 1·3 (0·3) 1·3 (0·3) 
LDL-cholesterol (mmol/L)  3.8 (1.0) 3.8 (1.0) 3.5 (0.7) 3.5 (0.8) 
Serum triglycerides (mmol/L)  1·6 (1·2 to 2·3) 1·6 (1·2 to 2·3) 1·4 (1·0 to 2·0) 1·4 (1·1 to 2·0) 
Fasting plasma glucose (mmol/L)  5·6 (5·1 to 6·6) 5·6 (5·1 to 6·6) 5·6 (5·1 to 6·5) 5·6 (5·1 to 6·6) 
Serum creatinine (umol/L)  99 (89 to 109) 98 (89 to 109) 99 (90 to 109) 99 (90 to 109) 
Presence of diabetes mellitus  1139 (26·5%) 1145 (26·.8%) 621 (26·8%) 630 (27·5%) 
Number of cardiovascular risk factors 3** 2055 (47·7%) 2044 (47·8%) 1201 (51·8%) 1141 (49·9%) 
 4 1416 (32·9%) 1417 (33·1%) 716 (30·9%) 746 (32·6%) 
 5 or more 834 (19·4%) 814 (19·0%) 400 (17·3%) 401 (17·5%) 
History of stroke / TIA (> 3 months ago)  507 (11·8%) 492 (11·5%) 233 (10·1%) 239 (10·4%) 
History of peripheral vascular disease  359 (8·3%) 383 (9·0%) 160 (6·9%) 150 (6·6%) 
Presence of atrial fibrillation  60 (1·4%) 60 (1·4%) 36 (1·6%) 32 (1·4%) 
Prior antihypertensive treatment   3961 (92·0%) 3924 (91·8%) 2118 (91·4%) 2106 (92·0%) 
Prior lipid-lowering treatment  490 (11·4%) 478 (11·2%) 29 (1·.3%) 22 (1·0%) 
Prior aspirin use  1083 (25·2%) 1040 (24·3%) 533 (23·0%) 519 (22·7%) 
Table: 2a.  Incidence rates for both total and cause specific mortality amongst those assigned to the two blood pressure lowering treatments in the 
ASCOT-Legacy cohort, during the in-trial period, post-trial period and throughout all follow-up  
 
  In trial (BPLA) (mean follow-up,  5·5 year)   Post-BPLA (mean follow-up, 10·7 years)   Total follow-up (mean follow-up, 15·7 years) 
  
Atenolol-based 
(N=4275)   
Amlodipine-based 
(N=4305)   
Atenolol-based 
(N=3613)   
Amlodipine-based 
(N=3688)   
Atenolol -based 
(N=4275)   
Amlodipine-based 
(N=4305) 
Cause of death n  Rate*   n Rate*   n  Rate*   n Rate*   n  Rate*   n  Rate* 
All-cause 370  1·62   347  1·50   1270  3·97   1295  3·98   1640  2·99   1642  2·95 
CV 149  0·65   115  0·50   474  1·48   472  1·45   623  1·13   587  1·05 
CHD 86  0·38   66  0·29   127  0·40   132  0·41   213  0·39   198  0·36 
Stroke 30  0·13   21  0·09   69  0·22   51  0·16   99  0·18   72  0·13 
Non-CV 221  0·97   232  1.00   796  2·49   823  2·53   1017  1·85   1055  1·90 
Cancer 135  0·59   146  0·63   440  1·37   451  1·39   575  1·05   597  1·07 
*Rate per 100 person years 
Atenolol-based regimen: atenolol adding thiazide diuretic as required; Amlodipine-based regimen: amlodipine adding perindopril as required 
 Table: 2b.  Incidence rates for the cause specific mortality amongst those assigned to either atorvastatin or a placebo in the lipid lowering arm of the 
ASCOT-Legacy cohort, during the in-trial period, post-trial period and throughout all follow-up  
  In-trial (LLA) (mean follow-up, 3·1 year)   Post-LLA  (mean follow-up, 13·2 year)   Total follow-up (mean follow-up, 15·7 year) 
  Placebo (N=2288)   Atorvastatin (N=2317)   Placebo (N=2198)   Atorvastatin (N=2234)   Placebo (N=2288)   Atorvastatin (N=2317) 
Cause of death n Rate*   n Rate*   n  Rate*   n  Rate*   n  Rate*   n  Rate* 
All-cause 90 1.28   83  1·18   813  3·67   782  3·42   903  3·09   865  2·89 
CV 36  0.51   30  0·43   289  1·30   255  1·11   325  1·11   285  0·95 
CHD 19  0.27   19  0·27   84  0·38   62  0·27   103  0·35   81  0·27 
Stroke 8  0.11   6  0.09   35  0·16   39  0·17   43  0·15   45  0·15 
Non-CV 54  0.77   53  0·75   524 2·36   527  2·30   578  1·98   580  1·94 
Cancer 37  0.53   38  0·54   297  1·34   292  1·28   334  1·14   330  1·10 
 
 
* Rate per 100 person years 
LLA: Lipid lowering arm; CV : cardiovascular ; CHD: coronary heart disease 
  
 Table: 3a.  Hazard ratios of both total and the cause-specific mortality amongst those assigned to amlodipine-based therapy as compared to the 
atenolol-based treatment in the ASCOT-Legacy cohort, during the in-trial, and the total follow-up period 
 BPLA in-trial period (Hazard ratio[95%CI]) Total follow-up (Hazard ratio[95%CI]) 
Cause of death Unadjusted P-value Adjusted* P-value Unadjusted P-value Adjusted* P-value 
All-cause 0·93 (0·80, 1·07) p=0·3130 0·91 (0·78, 1·05) p=0·2012 0·99 (0·92, 1·06) p=0·6722 
0·97 (0·90, 
1·04) p=0·3411 
Cardiovascular  0·76 (0·60, 0·97) p=0·0302 0·74 (0·58, 0·95) p=0·0177 0·93 (0·83, 1·04) p=0·1909 
0·90 (0·81, 
1·01) p=0·0776 
CHD 0·76 (0·55, 1·05) p=0·0930 0·74 (0·53, 1·02) p=0·0625 0·92 (0·76, 1·11) p=0·3786 
0·88 (0·73, 
1·07) p=0·2148 
Stroke 0·69 (0·40, 1·21) p=0·1969 0·69 (0·40, 1·21) p=0·2013 0·72 (0·53, 0·97) p=0·0316 
0·71 (0·53, 
0·97) p=0·0305 
Non-CV 1·04 (0·86, 1·25) p=0·6965 1·02 (0·85, 1·23) p=0·8292 1·02 (0·94, 1·11) p=0·6403 
1·01 (0·92, 
1·10) p=0·8880 
Cancer 1·07 (0·85, 1·35) p=0·5720 1·06 (0·84, 1·34) p=0·6101 1·02 (0·91, 1·15) p=0·7090 
1·01 (0·90, 
1·14) p=0·8304 
*Adjusted for baseline age, sex, ethnicity, systolic blood pressure, total cholesterol, body mass index, diabetes, smoking status, years of education (socio-economic 
status), randomization to the lipid lowering arm (placebo or atorvastatin) or not 
CHD: coronary heart disease; non-CV: non-cardiovascular cause of death.  
 
  
 Table: 3b.  The risk (hazard ratios) of the cause specific mortality amongst those assigned to the atorvastatin or a placebo in the lipid-lowering arm of 
the ASCOT-Legacy cohort, during the in trial, and total follow-up period 
 
 LLA in-trial period (Hazard ratio[95%CI]) Total follow-up (Hazard ratio[95%CI]) 
Cause of death Unadjusted P-value Adjusted* P-value Unadjusted P-value Adjusted* P-value 
All-cause 0·92 (0·68, 1·24) p=0·5970 0·93 (0·69, 1·25) p=0·6379 0·93 (0·85, 1·02) p=0·1211 0·92 (0·84, 1·01) p=0·0913 
Cardiovascular 0·83 (0·51, 1v35) p=0·4483 0·85 (0·52, 1·38) p=0·5128 0·85 (0·73, 1·00) p=0·0459 0·85 (0·72, 0·99) p=0·0395 
CHD 0·99 (0·53, 1·87) p=0·9805 1·02 (0·54, 1·92) p=0·9594 0·77 (0·57, 1·03) p=0·0735 0·.78 (0·58, 1·04) p=0·0884 
Stroke 0·75 (0·26, 2·17) p=0·5995 0·80 (0·27, 2·32) p=0·6774 1·02 (0·67, 1·55) p=0·9353 1·02 (0·67, 1·55) p=0·9238 
Non-CV 0·99 (0·67, 1·44) p=0·9393 0·98 (0·67, 1·43) p=0·9227 0·97 (0·87, 1·09) p=0·6420 0·96 (0·86, 1·08) p=0·5440 
Cancer 1·03 (0·65, 1·62) p=0·9011 1·01 (0·64, 1·59) p=0·9598 0·96 (0·82, 1·12) p=0·5932 0·95 (0·82, 1·11) p=0·5023 
*Adjusted for age, sex, ethnicity, systolic blood pressure, total cholesterol, body mass index, diabetes at baseline, smoking status, years of education 
(socio-economic status), randomization to the blood pressure lowering treatment 
CHD: coronary heart disease; non-CV: non-cardiovascular cause of death. 
 
 
 
  
  
Table: 4.  Numbers, incident rates and the risk (hazard ratios) of the cause specific deaths amongst those assigned to amlodipine-based treatment 
compared with those on atenolol-based treatment, stratified by the allocation to LLA or not (the non-LLA group)  
 
 
    Atenolol-based Amlodipine-based Risk 
  
Cause of 
death 
LLA  or not n Rate* n Rate* Adjusted HR (95% CI)** P-value Interaction p-
value# 
All-cause Non-LLA group 769 3·05 745 2·84 0·91 (0·83, 1·01) p=0·0784 
 
 
LLA group 871 2·93 897 3·05 1·02 (0·93, 1·12) p=0·7093 p=0·1222 
Cardiovascul
ar  
Non-LLA group 325 1·29 275 1·05 0·79 (0·67, 0·93) p=0·0046 
 
  LLA group 298 1·00 312 1·06 1·03 (0·88, 1·21) p=0·6999 p=0·0.0220 
CHD Non-LLA group 125 0·50 102 0·39 0·76 (0·59, 0·99) p=0·0439 
 
 
LLA group 88 0·30 96 0·33 1·06 (0·80, 1·42) p=0·6706 p=0·0952 
Stroke Non-LLA group 49 0·19 34 0·13 0·67 (0·43, 1·04) p=0·0751 
 
  LLA group 50 0·17 38 0·13 0·76 (0·50, 1·16) p=0·1977 p=0·6982 
Non-CV Non-LLA group 444 1·76 470 1·79 1·00 (0·88, 1·14) p=0·9803 
 
  LLA group 573 1·93 585 1·99 1·01 (0·90, 1·13) p=0·8569 p=0·9193 
Cancer Non-LLA group 247 0·98 261 1·00 1·01 (0·85, 1·20) p=0·9436 
 
  LLA group 328 1·11 336 1·14 1·02 (0·87, 1·19) p=0·8163 p=0·9207 
 
* rate per 100 person years 
**Adjusted for age, sex, ethnicity, socio-economic status, body-mass index, systolic BP, total cholesterol, the presence of diabetes, & smoking history. 
#P-value from test on interaction from adjusted models. 
LLA: Lipid lowering arm (including those on atorvastatin or a placebo), non-LLA group: those not included in the LLA because of high baseline total 
cholesterol  
Atenolol-based regimen: atenolol adding thiazide diuretic as required;  Amlodipine-based regimen: amlodipine adding perindopril as required 
CHD: coronary heart disease; non-CV: non-cardiovascular cause of death 
Figure Legend 
 
Figure 1: The ASCOT-Legacy study profile: patient population stratified by the treatment allocation 
 
Figure 2 (a-d): The risk of cause-specific deaths among those allocated to the amlodipine based treatment as 
compared to those on the atenolol-based treatment in the 16 year follow up of the ASCOT-Legacy cohort assigned 
to the BPLA 
 
Figure 3 (a-d): The risk of cause-specific deaths among those allocated to the atorvastatin  compared with placebo 
in the 16 year follow up of the ASCOT-Legacy cohort assigned to LLA 
 
Figure 4: The risk (hazard ratios) of the cause specific mortality amongst those assigned to two treatments in the 
BPLA and LLA of the ASCOT-Legacy cohort 
 
 
 
  
 Figure 1:  The ASCOT-Legacy study profile: patient population stratified by the treatment allocation 
 
 
 
 
BPLA: blood pressure lowering arm ; LLA: lipid-lowering arm 
  
Figure 2a: Kaplan-Meier plots for cumulative incidence of all-cause mortality amongst those allocated to the 
two BP-treatment groups 
 
 
 
 
 
 
HR: hazard ratio 
  
Figure 2b: KM plots for the cumulative incidence of the cardiovascular mortality amongst those allocated to 
the two BP-treatment groups 
 
 
 
 
CV: cardiovascular mortality 
  
Figure 2c: KM plots for the cumulative incidence of the coronary heart disease mortality amongst those 
allocated to the two BP-treatment groups 
 
 
 
CHD: coronary heart disease -related mortality 
  
 
Figure 2d: KM plots for the cumulative incidence of the stroke mortality amongst those allocated to the two 
BP-treatment groups 
 
 
 
 
 
  
 Figure 3a: KM plots for cumulative incidence of the all-cause mortality amongst those allocated to the 
atorvastatin or a placebo 
  
 
 
 
  
 
Figure 3b: KM plots for the cumulative incidence of the cardiovascular mortality amongst those allocated to 
the atorvastatin or a placebo 
 
 
 
 
  
 
Figure 3c: KM plots for the cumulative incidence of the coronary heart disease mortality amongst those 
allocated to the atorvastatin or a placebo 
 
 
 
 
 
  
Figure 3d: KM plots for the cumulative incidence of the stroke mortality amongst those allocated to the 
atorvastatin or a placebo 
 
 
 
 
 
Figure 4 The risk (hazard ratios) of the cause specific mortality amongst those assigned to the two treatment 
groups in the BPLA and LLA of the ASCOT trial 
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